WO2001024829A3 - Binding agents - Google Patents

Binding agents Download PDF

Info

Publication number
WO2001024829A3
WO2001024829A3 PCT/GB2000/003792 GB0003792W WO0124829A3 WO 2001024829 A3 WO2001024829 A3 WO 2001024829A3 GB 0003792 W GB0003792 W GB 0003792W WO 0124829 A3 WO0124829 A3 WO 0124829A3
Authority
WO
WIPO (PCT)
Prior art keywords
binding agents
derivatives
complexes
internalised
bind
Prior art date
Application number
PCT/GB2000/003792
Other languages
French (fr)
Other versions
WO2001024829A2 (en
Inventor
Rodney E Phillips
Peter Roderick Dunbar
Vincenzo Cerundolo
Andrew Sewell
Original Assignee
Isis Innovation
Rodney E Phillips
Peter Roderick Dunbar
Vincenzo Cerundolo
Andrew Sewell
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation, Rodney E Phillips, Peter Roderick Dunbar, Vincenzo Cerundolo, Andrew Sewell filed Critical Isis Innovation
Priority to CA002386307A priority Critical patent/CA2386307A1/en
Priority to EP00969664A priority patent/EP1218034A2/en
Priority to AU79323/00A priority patent/AU7932300A/en
Publication of WO2001024829A2 publication Critical patent/WO2001024829A2/en
Publication of WO2001024829A3 publication Critical patent/WO2001024829A3/en

Links

Classifications

    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6425—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the peptide or protein in the drug conjugate being a receptor, e.g. CD4, a cell surface antigen, i.e. not a peptide ligand targeting the antigen, or a cell surface determinant, i.e. a part of the surface of a cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/66—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells
    • A61K47/665—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid the modifying agent being a pre-targeting system involving a peptide or protein for targeting specific cells the pre-targeting system, clearing therapy or rescue therapy involving biotin-(strept) avidin systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nanotechnology (AREA)
  • Cell Biology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Medical Informatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

MHC peptide complexes or derivatives thereof can bind to T cell receptors in a specific manner at much higher temperatures than previously disclosed. Active agents linked to such complexes, or to derivatives thereof, can be internalised by T cells.
PCT/GB2000/003792 1999-10-04 2000-10-04 Binding agents WO2001024829A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
CA002386307A CA2386307A1 (en) 1999-10-04 2000-10-04 Binding agents
EP00969664A EP1218034A2 (en) 1999-10-04 2000-10-04 Binding agents
AU79323/00A AU7932300A (en) 1999-10-04 2000-10-04 Binding agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9923337.1A GB9923337D0 (en) 1999-10-04 1999-10-04 Binding agents
GB9923337.1 1999-10-04

Publications (2)

Publication Number Publication Date
WO2001024829A2 WO2001024829A2 (en) 2001-04-12
WO2001024829A3 true WO2001024829A3 (en) 2002-01-03

Family

ID=10862011

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/003792 WO2001024829A2 (en) 1999-10-04 2000-10-04 Binding agents

Country Status (5)

Country Link
EP (1) EP1218034A2 (en)
AU (1) AU7932300A (en)
CA (1) CA2386307A1 (en)
GB (1) GB9923337D0 (en)
WO (1) WO2001024829A2 (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
FR2798128A1 (en) * 1999-09-06 2001-03-09 Inst Nat Sante Rech Med MEANS OF DETECTION AND PURIFICATION OF T CD8 + LYMPHOCYTE POPULATIONS SPECIFIC TO PEPTIDES PRESENT IN THE HLA CONTEXT
WO2001036453A2 (en) * 1999-11-15 2001-05-25 Ludwig Institute For Cancer Research Ny-eso-1 nanopeptide derivatives, and uses thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026962A1 (en) * 1995-02-28 1996-09-06 The Board Of Trustees Of The Leland Stanford Junior University Mhc-antigen complexes for detecting and purifying antigen-specific t cells
FR2798128A1 (en) * 1999-09-06 2001-03-09 Inst Nat Sante Rech Med MEANS OF DETECTION AND PURIFICATION OF T CD8 + LYMPHOCYTE POPULATIONS SPECIFIC TO PEPTIDES PRESENT IN THE HLA CONTEXT
WO2001036453A2 (en) * 1999-11-15 2001-05-25 Ludwig Institute For Cancer Research Ny-eso-1 nanopeptide derivatives, and uses thereof

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
GOLETZ T J ET AL: "DELIVERY OF ANTIGENS TO THE MHC CLASS I PATHWAY USING BACTERIAL TOXINS", HUMAN IMMUNOLOGY, NEW YORK, NY, US, vol. 54, no. 2, 1 May 1997 (1997-05-01), pages 129 - 136, XP002051134, ISSN: 0198-8859 *
OGG G. S. ET AL: "Sensitization of tumour cells to lysis by virus-specific CTL using antibody-targeted MHC class I/peptide complexes", BRITISH JOURNAL OF CANCER, vol. 82, no. 5, March 2000 (2000-03-01), pages 1058 - 1062, XP001020805 *
STENMARK H ET AL: "Peptides fused to the amino-terminal end of diphtheria toxin are translocated to the cytosol.", JOURNAL OF CELL BIOLOGY, (1991 JUN) 113 (5) 1025-32., XP001020812 *
YOUDE S. J. ET AL: "Use of fluorogenic histocompatibility leukocyte antigen-A*0201/HPV 16 E7 peptide complexes to isolate rare human cytotoxic T-lymphocyte-recognizing endogenous human papilloma antigens", CANCER RESEARCH, vol. 60, 15 January 2001 (2001-01-15), pages 365 - 371, XP002167445 *

Also Published As

Publication number Publication date
GB9923337D0 (en) 1999-12-08
EP1218034A2 (en) 2002-07-03
AU7932300A (en) 2001-05-10
WO2001024829A2 (en) 2001-04-12
CA2386307A1 (en) 2001-04-12

Similar Documents

Publication Publication Date Title
AU5865300A (en) Platinum-ruthenium-nickel alloy for use as a fuel cell catalyst
AU2426401A (en) Enhanced methanol utilization in direct methanol fuel cell
BG103805A (en) Trifluoromethylalkylaminotriazolopyrimidines with fungicidal effect
ZA200107409B (en) Fuel composition.
AU2001260606A1 (en) Constituent part for fuel cell
AU1967301A (en) Method and system for dual-network address utilization by virtual tunneling
EP1185305A4 (en) Ligand-conjugated oligomeric compounds
HK1046989A1 (en) Movable anode fuel cell battery.
MXPA01013450A (en) Cytoplasmic transfer to de-differentiate recipient cells.
CA2379855A1 (en) Spreadsheet cell-data source binding
MXPA01010639A (en) Lanthanum nickel compound/metal mixture as a third electrode in a metal-air battery.
AU6229700A (en) Direct antifreeze cooled fuel cell
DE59800439D1 (en) Crosslinkable powder composition redispersible in water
AU6906200A (en) Fuel cell system
DE60025409D1 (en) fuel cell stack
CA2450650A1 (en) Encapsulated cell therapy
AU2001294226A1 (en) Dual purpose fuel for gasoline-driven automobile and fuel cell system, and system for storage and/or supply thereof
WO2001024829A3 (en) Binding agents
WO2000060355A3 (en) Lfa-1 regulatory binding site and uses thereof
AU6199001A (en) Battery, especially a flat cell
AU4474401A (en) Fuel for use in fuel cell
MXPA02002736A (en) Via filled interconnect for solid oxide fuel cells.
AU7099900A (en) Peptides that bind to urokinase receptor
AU4688401A (en) Fuel for use in fuel cell system
ZA200001232B (en) Membrane-electrode unit for a fuel cell.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 2386307

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2000969664

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 79323/00

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2000969664

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Ref document number: 2000969664

Country of ref document: EP